Plaintiff
5 cases as plaintiff.
Company overview. Amneal Pharmaceuticals LLC is the operating entity of Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), a publicly traded, fully integrated generics and specialty pharmaceutical company headquartered in Bridgewater, New Jersey. Founded in 2002 by brothers Chirag and Chintu Patel and publicly listed in 2018 after a reverse merger with Impax Laboratories, the company employs roughly 8,500–8,700 people and reported FY2024 net revenue of about $2.8 billion (≈$3.0 billion in FY2025). Public sources place its market cap in the $5.5–6.3 billion range.
Products / operations. Amneal develops, manufactures, and distributes a portfolio of roughly 280+ drug products across three segments: Affordable Medicines (retail generics, sterile injectables, and biosimilars — including oral solids, liquids, nasal sprays, transdermals, and ophthalmics), Specialty (branded CNS and endocrine products such as Rytary, Unithroid, and Ongentys), and AvKARE (pharmaceutical distribution to U.S. federal agencies including DoD and VA). It bills itself as the #4 U.S. generics portfolio by prescriptions and sales, with operations in the U.S., India, and Ireland.
Patent-litigation posture. Amneal is an operating company defending against a brand-owner suit — not an NPE. The tracked database shows one case, with Amneal as defendant and zero as plaintiff: a Hatch-Waxman/ANDA action filed in the District of Delaware (the typical venue for such cases), not a plaintiff-friendly forum like the Eastern District of Texas.
Notable case. In Neurelis, Inc. v. Amneal Pharmaceuticals LLC et al. (D. Del., filed March 11, 2026), Neurelis — maker of Valtoco® (diazepam) nasal spray — sued Amneal over ANDA No. 219109 seeking approval of generic 7.5 mg and 10 mg diazepam nasal sprays, asserting patents covering intranasal benzodiazepine compositions and treatment methods (including U.S. Patent Nos. 12,337,061 and 12,521,400). The case was consolidated before Judge Maryellen Noreika with related Neurelis ANDA litigation against Padagis and Lupin. It reflects Amneal's routine generics business of filing Paragraph IV challenges to branded CNS products. Amneal also acquired biopharmaceutical firm Kashiv BioSciences in August 2026.
Watchlist
Email-only, free, anonymous. We'll notify you when Amneal Pharmaceuticals LLC files another patent-infringement lawsuit. One-click unsubscribe from any alert.
Petition by Amneal Pharmaceuticals LLC challenging the '306 patent. The Board did not institute review on the merits; cited as Amneal Pharms. LLC v. Jazz Pharms. Ireland Ltd., 2016 WL 5222883 (PTAB July 28, 2016).
Inter partes review of U.S. 8,731,963. The Board held claims 24, 26, and 27 unpatentable on obviousness and on-sale/public-disclosure grounds relating to the Xyrem REMS. Related appeal No. 2017-1671 settled during appeal.
Inter partes review petition filed by Amneal Pharmaceuticals LLC against Jazz Pharmaceuticals. It was instituted with joinder and terminated on July 27, 2016, resolved by the final written decision in IPR2015-00548.
Inter partes review of U.S. 8,589,182 B1. The PTAB held all challenged claims unpatentable as obvious over FDA Xyrem advisory-committee materials; rehearing was denied and the decision was affirmed by the Federal Circuit.
Amneal Pharmaceuticals LLC, joined by Par Pharmaceutical and Wockhardt Bio AG, filed an IPR against Jazz on the '106 patent. The PTAB held all claims unpatentable as obvious; rehearing was denied.